Alvotech and advanz pharma receive marketing authorisations for gobivaz®, a biosimilar to simponi® (golimumab), from the mhra

Reykjavik,  iceland and london, uk (november 06, 2025) — alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma holdco limited (“advanz pharma”), a uk headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in europe, today announced that the uk medicines and healthcare products regulatory agency (mhra) has granted marketing authorisations for all four presentations of gobivaz®, alvotech's biosimilar to simponi® (golimumab).
ALVO Ratings Summary
ALVO Quant Ranking